

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 July 2019 (04.07.2019)



(10) International Publication Number
WO 2019/129261 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/CN2018/125375

(22) International Filing Date:

29 December 2018 (29.12.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2017/120392

30 December 2017 (30.12.2017) CN

(71) Applicant: **BEIGENE, LTD.**; C/o Maurant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman Cayman Islands KY1-1108 (GB).

(71) Applicant (for SC only): **ZHANG, Tong** [CN/CN]; No.30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).

(72) Inventors: **XUE, Liu**; No.30 Science Park Road, Zhongguancun Life Science, Park, Changping District, Beijing 102206 (CN). **LIU, Qi**; No.30 Science Park Road, Zhongguancun Life Science, Park, Changping District, Beijing 102206 (CN). **WEI, Min**; No.30 Science Park Road, Zhongguancun Life Science, Park, Changping District, Beijing 102206 (CN). **LI, Kang**; No.30 Science Park Road, Zhongguancun Life Science, Park, Changping District, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3 FL, Building 2, Yard 3, FengXiuZhongLu Road, Haidian District, Beijing 100094 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2019/129261 A1

(54) Title: ANTI-TIGIT ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS

(57) Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti- TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.